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Text
Docetaxel, Adriamycin, 
Cyclophosphamide (TAC) is 
considered today as one 
treatment option for patients with 
node-positive primary breast 
cancer. However, treatment is 
associated with anaemia grade 1-
4 (2-4) in up to 95% (36%) of 
patients. We prospectively 
investigated the use of a primary 
prophylaxis with Darbepoetin alfa 
once every 3 weeks in 35 patients 
receiving six to eight cycles of TAC 
as neoadjuvant treatment for 
breast cancer. Darbepoetin 
treatment started on day 1 of a 
TAC cycle if haemoglobin (Hb) was 
£ 14.0 g/dl. Dosage was adapted 
to 9 µg/kg if Hb was £ 13.0 g/dl 
on day 21 of the previous cycle, to 
4.5 µg/kg if Hb was between 13.0 
and 14.0 g/dl and was 
discontinued if Hb increased to ³ 
14 g/dl. The primary aim was to 
prevent Hb levels £ 12 g/dl before 
surgery. During 112 (50.2%) and 
93 (41.7%) of 223 cycles, 4.5 µg/
kg and 9 µg/kg Darbepoetin were 
given, respectively. Dosage was 
decreased from 9 to 4.5 µg/kg in 
21 (60%) patients and 28 
(12.4%) cycles. Treatment was 
discontinued due to Hb > 14.0 g/
dl in 12 (34.3%) patients and 13 (5.4%) cycles. Hb level on day 21 
of the last cycle was £ 12.0 g/dl in 
4 (11.4%) patients. Eighteen 
(51.4%) patients during 36 
(16.1%) cycles showed Hb levels 
£ 12 g/dl throughout treatment. 
No NCI-CTC grade 2 to 4 anaemia 
was observed. Symptoms of 
fatigue (FACT-AN) decreased 
slightly throughout treatment. 
Anaemia during TAC 
chemotherapy can be avoided by 
a single injection of Darbepoetin 
alfa every 3 weeks.
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